Financial Assistance
Newsletter Sign-up
Need Appointment
Contact Us
About Us

Rush University
For Physicians
For Rush Employees
For Students
Bill Payment Center
<< Previous | New Search | Return to Search Results | Next >>

Dusan Stefoski, MD

Dusan Stefoski, MD
Appointment Request

Or call
(888) 352-RUSH for help arranging an appointment.
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Associate Professor
Medical or Graduate Education: University of Zagreb School of Medicine, Croatia
Residency: Rush University Medical Center - Neurology
Fellowship: Rush University Medical Center - Multiple Sclerosis
Clinical Expertise:
  • Ataxia
  • Botulinum toxin injections
  • Lumbar puncture
  • Multiple sclerosis
  • Optic neuritis
  • Transcranial magnetic stimulation
Research Interests:
  • Multiple sclerosis
Languages Spoken:
  • Croatian
  • German
  • Serbian
Google Map
  • University Neurologists
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 309
  • Chicago, IL  60612
  • Phone: (312) 942-8011
  • Fax: (312) 563-2337
  • View Larger MapDriving Directions

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
    Havrdova E, Giovannoni G, Stefoski D, Forster S, Umans K, Mehta L, Greenberg S, Elkins J
    Mult. Scler.
    2013 Sep 10
  2. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; for the SELECT study investigators.
    Lancet. 2013
    2013 Apr 3. doi:pii: S0140-6736(12)62190-4. 10.1016/S0140-6736(12)62190-4. [Epub ahead of print]
  3. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.
    Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R.
    J Immunol. 2012
    2012 Nov 1
    189(9):4602-11. doi: 10.4049/jimmunol.1200486. Epub 2012 Sep 24.
  4. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Ko MY, Stefoski D, Balabanov R, Vennegoor A, Wattjes MP, van Munster ET, Killestein J, Polman CH.
    2011 Sep 6
  5. Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis.
    Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Clarke R, Stefoski D, Balabanov R.
    J Neurosci.
    2011 Jun 8
  6. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination
    Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R
    J Neuroimmunol
    2011 Jan 21
  7. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis
    Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V
    J Neurol Sci
    2010 Mar 15
  8. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis
    Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R
    J Neuroimmune Pharmacol
    2010 Jun
  9. Freedom from disease activity in multiple sclerosis
    Havrdova E, Galetta S, Stefoski D, Comi G
    2010 Apr 27
    74 Suppl 3:S3-7
  10. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R
    Lancet Neurol
    2009 Mar
  11. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
    Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH
    Lancet Neurol
    2009 Mar
  12. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis
    Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL
    J Neuroimmunol
    2009 Jun 25

Find a Doctor | Patient & Visitor Services | Health Information | Clinical Services | Events & Classes | News Room | Clinical Trials | Research at Rush
Nursing at Rush | Work at Rush | Giving to Rush | Directions to Rush | Disclaimer | Privacy Statement
For Physicians | For Rush Employees | For Students | Bill Payment Center | Site Map
© Rush University Medical Center
1653 W. Congress Parkway, Chicago, Illinois 60612